Search results for "s disease"

showing 10 items of 5637 documents

The Guinea Worm: A Zoonotic Parasite of Dogs

2017

0301 basic medicineDracunculiasisDracunculiasis030231 tropical medicineZoologyDracunculus NematodeBiologymedicine.disease03 medical and health sciencesDracunculus NematodeDogs030104 developmental biology0302 clinical medicineInfectious DiseasesZoonosesAfricamedicineAnimalsHumansParasite hostingParasitologyTrends in Parasitology
researchProduct

The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

2019

For many decades classical anti-tumor therapies included chemotherapy, radiation and surgery; however, in the last two decades, following the identification of the genomic drivers and main hallmarks of cancer, the introduction of therapies that target specific tumor-promoting oncogenic or non-oncogenic pathways, has revolutionized cancer therapeutics. Despite the significant progress in cancer therapy, clinical oncologists are often facing the primary impediment of anticancer drug resistance, as many cancer patients display either intrinsic chemoresistance from the very beginning of the therapy or after initial responses and upon repeated drug treatment cycles, acquired drug resistance deve…

0301 basic medicineDrugCancer Researchmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectTranslational researchApoptosisDrug resistanceMonoclonal antibodyBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Hedgehog ProteinsEpigeneticsProtein Kinase Inhibitorsmedia_commonPharmacologyChemotherapybusiness.industryCancerImmunotherapyProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbusinessProteasome InhibitorsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model

2017

The therapy of inflammatory bowel diseases is still rather inefficient, and about 80% of patients require surgery at some stage. Improving the treatments by more efficient medication is, therefore, an urgent medical need. The objective of this project was to demonstrate targeted delivery of Cyclosporine-A (CYA) to the inflamed areas of the intestinal mucosa after oral administration, enabling improved alleviation of the symptoms and, at the same time, reduced systemic drug absorption and associated adverse effects. As had already been demonstrated in previous studies, nano- to micrometer-sized drug particles will accumulate at inflamed mucosal areas, providing a platform for such purposes. …

0301 basic medicineDrugColonPolymersmedia_common.quotation_subjectAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyPharmacologyInflammatory bowel diseaseMice03 medical and health sciencesDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIntestinal mucosaOral administrationAnimalsMedicineLactic AcidIntestinal MucosaParticle SizeAdverse effectmedia_commonDrug CarriersMice Inbred BALB CCrohn's diseasebusiness.industryGeneral MedicineInflammatory Bowel Diseases021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityDisease Models Animal030104 developmental biologyCyclosporineNanoparticlesNanocarriers0210 nano-technologybusinessPolyglycolic AcidBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Abacavir Induces Arterial Thrombosis in a Murine Model.

2018

Background The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking. Methods The present study appraised the effects of abacavir in a well-validated animal model of arterial thrombosis. The role of ATP-P2X7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other nucleoside reverse-transcriptase inhibitors (NRTIs) were evaluated and compared to those of abacavir. Results Abacavir dose-dependently promoted thrombu…

0301 basic medicineDrugMaleAnti-HIV Agentsmedia_common.quotation_subject030204 cardiovascular system & hematologyPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicineimmune system diseasesAbacavirmedicineImmunology and AllergyAnimalsRofecoxibmedia_commonMice KnockoutDose-Response Relationship Drugbusiness.industryPurinergic receptorAntagonistvirus diseasesThrombosisPurinergic signallingmedicine.diseaseThrombosisDideoxynucleosidesDisease Models Animal030104 developmental biologyInfectious DiseasesReceptors Purinergic P2X7businessmedicine.drugThe Journal of infectious diseases
researchProduct

Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation.

2017

: There is a long-lasting controversy surrounding an association between abacavir (ABC) and an increased risk of cardiovascular disease in HIV-positive patients. Although differing in their specifics, a number of published cohort studies and clinical trials support such an association, usually relating it to recent exposure to the drug, independently of traditional predisposing factors. However, other clinical trials have failed to reveal such a relation and have pointed to methodological differences to explain discrepancies. Significantly, the controversy has been fueled by the lack of a credible mechanism of action to justify the putative detrimental actions of ABC. There is a myriad of c…

0301 basic medicineDrugVasculitisAnti-HIV Agentsmedia_common.quotation_subjectImmunologyHIV InfectionsDiseasePharmacologyBioinformaticsProinflammatory cytokine03 medical and health sciencesParacrine signallingchemistry.chemical_compound0302 clinical medicineAbacavirImmunology and AllergyMedicineHumans030212 general & internal medicineCyclic guanosine monophosphatemedia_commonbusiness.industryAtherosclerosis030112 virologyDideoxynucleosidesClinical trialInfectious DiseaseschemistryMechanism of actionCardiovascular Diseasesmedicine.symptombusinessmedicine.drugAIDS (London, England)
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin

2015

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing ribavirin are reviewed. Ribavirin is highly soluble, but its permeability characteristics are not well defined. Therefore according to the Biopharmaceutical Classification System, and taking a “worst case” approach, ribavirin should be assigned to class III. As ribavirin is transported across the brush border membrane of the human jejunum by hCNT2, it shows saturable uptake in the intestine. However, no common excipients have been shown to compete for ribavirin absorption, nor have problems with BE of immediate release rib…

0301 basic medicineDrugribavirinDrug Compoundingvirusesmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceCapsulesPharmacologyBioequivalenceAntiviral Agents030226 pharmacology & pharmacyPermeabilityArticleDosage formExcipients03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTherapeutic indexHumansMedicineImmediate releasemedia_commonbusiness.industrysolubilityRibavirinvirus diseasesbiochemical phenomena metabolism and nutritionBCSbiowaiver030112 virologydigestive system diseasesBiopharmaceuticalTherapeutic EquivalencychemistryManufacturing methodsbusinessabsorptionTabletsJournal of Pharmaceutical Sciences
researchProduct

SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective

2020

In less than five months, COVID-19 has spread from a small focus in Wuhan, China, to more than 5 million people in almost every country in the world, dominating the concern of most governments and public health systems. The social and political distresses caused by this epidemic will certainly impact our world for a long time to come. Here, we synthesize lessons from a range of scientific perspectives rooted in epidemiology, virology, genetics, ecology and evolutionary biology so as to provide perspective on how this pandemic started, how it is developing, and how best we can stop it.

0301 basic medicineEconomic growth[SDV]Life Sciences [q-bio]Gene ExpressionSeverity of Illness IndexDisease OutbreaksBiological CoevolutionChiropteraPandemicEpidemiologyPhylogenyComputingMilieux_MISCELLANEOUSEutheriaPhylodynamics3. Good healthEuropeInfectious DiseasesHost susceptibilityHost-Pathogen InteractionsSpike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Coronavirus InfectionsMicrobiology (medical)medicine.medical_specialtyAsiaCoronavirus disease 2019 (COVID-19)Pneumonia Viral030106 microbiologyFILOGENIAPeptidyl-Dipeptidase ABiologyMicrobiologyArticleBetacoronavirus03 medical and health sciencesPoliticsGeneticsmedicineAnimalsHumansChinaPandemicsMolecular BiologyEcology Evolution Behavior and SystematicsSARS-CoV-2Public healthPerspective (graphical)COVID-19Immunity InnateCoronavirusImmune system030104 developmental biologyViral phylodynamicsNorth AmericaCoevolution
researchProduct

Parasites, pathogens, and other symbionts of copepods.

2021

There is a large diversity of eukaryotic symbionts of copepods, dominated by epizootic protists such as ciliates, and metazoan parasites. Eukaryotic endoparasites, copepod-associated bacteria, and viruses are less well known, partly due to technical limitations. However, new molecular techniques, combined with a range of other approaches, provide a complementary toolkit for understanding the complete symbiome of copepods and how the symbiome relates to their ecological roles, relationships with other biota, and responses to environmental change. In this review we provide the most complete overview of the copepod symbiome to date, including microeukaryotes, metazoan parasites, bacteria, and …

0301 basic medicineEnvironmental changeRange (biology)030231 tropical medicineZoologyBiologyCopepoda03 medical and health sciences0302 clinical medicinemedicineAnimalsSymbiosisEpizooticEcosystemMicrobiotafungiDinoflagellateEukaryotaBiotamedicine.diseasebiology.organism_classification030104 developmental biologyInfectious DiseasesMicrosporidiaParasitologyhuman activitiesCopepodBacteriaTrends in parasitology
researchProduct

2016

Summary Background Timely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy (ART), and mortality for 195 countries and territories from 1980 to 2015. Methods For countries without high-quality vital registration data, we estimated prevalence and incidence with data from antenatal care clinics and population-based seroprevalence surveys, and with assumptions by age and sex on initial CD4 distribution at infection, CD4 progression rates (probability of progre…

0301 basic medicineEpidemiologyImmunologyPopulation03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)VirologymedicineGlobal healthSeroprevalence030212 general & internal medicineYoung adulteducationeducation.field_of_studybusiness.industry1. No povertymedicine.diseaseMental health3. Good health030104 developmental biologyInfectious DiseasesSystematic reviewCohortbusinessDemographyThe Lancet HIV
researchProduct

Epidemiology of taeniosis/cysticercosis in Europe, a systematic review: eastern Europe

2018

Background Taenia solium and Taenia saginata are food-borne parasites of global importance. In eastern Europe only fragmented information is available on the epidemiology of these zoonotic parasites in humans and animal populations. In particular for T. solium, on-going transmission is suspected. The aim of this systematic review was to collect the available data and describe the current knowledge on the epidemiology of T. solium and T. saginata in eastern Europe. Methods Literature published in international databases from 1990 to 2017 was systematically reviewed. Furthermore, local sources and unpublished data from national databases were retrieved from local eastern European experts. The…

0301 basic medicineEpidemiologyPorcineIMPACT030231 tropical medicineReviewEastern Europe413 Veterinary scienceNeurocysticercosislcsh:Infectious and parasitic diseases03 medical and health sciences6190302 clinical medicineparasitic diseasesTaenia soliumMedicine and Health Scienceslcsh:RC109-216Veterinary SciencesSEROPREVALENCETaenia saginataBovineBOVINE CYSTICERCOSIS030108 mycology & parasitology3142 Public health care science environmental and occupational healthTaenia solium ; Taenia saginata ; Epidemiology ; Bovine ; Porcine ; Neurocysticercosis ; Eastern Europe3. Good healthPREVALENCEInfectious DiseasesParasitology
researchProduct